Recurrent, Severe Aphthous Stomatitis and Mucosal Ulcers as Primary Manifestations of a Novel STAT1 Gain-of-Function

Melinda Erdős1,2,3, Eszter Jakobicz4, Beáta Soltész1

  • 1Department of Infectious and Pediatric Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Insights

A novel gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1) causes immune dysfunction. This STAT1 mutation leads to severe aphthous stomatitis and esophagitis, not just chronic mucocutaneous candidiasis.

Area of Science:

  • Immunology
  • Genetics
  • Infectious Diseases

Background:

  • Gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (STAT1) are linked to chronic mucocutaneous candidiasis (CMC).
  • The clinical spectrum of STAT1 GOF mutations can include viral infections and autoimmune disorders.

Observation:

  • A patient presented with severe aphthous stomatitis, esophageal ulcers, and recurrent herpes simplex, with only partial CMC.
  • A novel heterozygous STAT1 variant (c.1219C>G; L407V) was identified in the patient and her daughter, confirmed as GOF.
  • Reduced IL-17A and IL-22 production by patient's immune cells was observed, suggesting impaired CD4+ T cell differentiation.

Findings:

  • The novel STAT1 mutation impairs the differentiation of CD4+ T cells into IL-17-producing cells.
  • This immune defect underlies the patient's unique clinical presentation dominated by severe mucosal inflammation.

Implications:

  • Severe recurrent aphthous stomatitis and esophagitis warrant evaluation for STAT1 GOF mutations.
  • The term "CMC" may be too narrow to encompass the full clinical spectrum of STAT1 GOF mutations.

Related Concept Videos

Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.7K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.1K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
652
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
436
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.0K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
963